Search results

Page results

• Peer review shines spotlight on collaborative excellence and challenges at the Red Cell Network HCC

  Every five years, a national Peer Review process casts a supportive but critical eye over red cell services across the UK.

• Contrast agents for MRI examinations

  This page provides information on examinations using contrast agents in MRI. It is intended for use by patients (or their families or carers) who have been referred to our service for imaging requiring contrast agents.

• Arif Ahmed, associate non-executive director

  Arif Ahmed is an entrepreneur and private equity investor in healthcare, technology, e-commerce and B2B services companies. He has a proven track record of scaling innovation in complex regulatory environments.

• New UCLH clinic opens to provide COVID-19 treatments for highest risk non-hospitalised patients

  University College London Hospitals (UCLH) is now administering new COVID-19 treatments for patients at highest risk in the community.

• New national study on long-term health impacts of COVID-19 launched

  UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.

• Varicocele embolisation

  This page tells you about the procedure known as varicocele (pronounced VARI-CO-SEAL) embolisation.

• Having proton beam therapy: information for children aged 5-8

  Having proton beam therapy: information for children aged 5-8 patient information page.

• Increase in delirium, rare brain inflammation and stroke linked to COVID-19

  Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.

• Second #GunnerGetJabbed event at the Emirates Stadium between 7-10 August

  A second mass vaccination event will be held over four days this month at Emirates Stadium in a bid to give thousands more people the chance to have their first or second dose of the Pfizer Covid-19 vaccine.

• Cystic fibrosis drug tested to fight inflammation in COVID-19

  Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.